Commentary|Videos|October 24, 2024
Long-Term Data for CPX-351 in Secondary AML
Author(s)Harry Erba, MD, PhD, James K. McCloskey, MD
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
Divarasib Improves Survival and Paves Way for New SOC in Pretreated KRAS G12C–Mutated NSCLC
2
Ivonescimab Plus Chemotherapy Represents a New SOC in First-Line Biliary Tract Cancer
3
SAFFRON Data Reveal New Global SOC in EGFR+ NSCLC With MET Overexpression and/or Amplification After Osimertinib
4
CLARITY-Gastric01 Shows OS Benefit With Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastroesophageal Carcinoma
5